Soriano-Ursúa MA1, Farfán-García ED2, López-Cabrera Y2, Querejeta E3, Trujillo-Ferrara JG2.
Neurotoxicology. 2014 Jan;40:8-15. doi: 10.1016/j.neuro.2013.10.005. Epub 2013 Nov 1.Boron-containing compounds (BCCs), particularly boron containing acids (BCAs), have become attractive moieties or molecules in drug development. It has been suggested that when functional groups with boron atoms are added to well-known drugs, the latter are conferred with greater potency and efficacy in relation to their target receptors. However, the use of BCAs in drug development is limited due to the lack of a toxicological profile. Read More